Canterbury DHB


Primary CNS Lymphoma

Treatment should be within a clinical trial where possible. There is no standard regimen for PCNSL but treatment should include high dose methotrexate (3-5 doses of ≥ 3 g/m2 delivered over a maximum of 2-3 hours at interval of not more than 2-3 weeks). The efficacy is improved by adding rituximab. Such treatment should be based on established protocols. See:

About this Canterbury DHB document (1603):

Document Owner:

Peter Ganly (see Who's Who)

Last Reviewed:

December 2021

Next Review:

December 2024


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 1603